Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

AtomicAIerts Dec. 5 at 12:52 PM

$QNCX AtomicAlerts Scalp Alert Direction: SHORT Entry: $3.6 TP1: $2.9 | TP2: $2.2 | TP3: $1.5 Stop Loss: $4.2 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 6:49 AM

1ightning® Premium Options Alert (Actionable) Ticker: $QNCX Contract: Dec 19 $2.5C Entry: 1.20 Exit: 1.66 Return: +37.94% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

GrandPoobahofBagholders Dec. 5 at 2:12 AM

$QNCX It sure would be nice to get positive Phase 3 data tomorrow morning!

1 · Reply

Iightning Dec. 5 at 12:38 AM

1ightning® Premium Options Alert (Actionable) Ticker: $QNCX Contract: Dec 19 $2.5C Entry: 1.20 Exit: 1.66 Return: +37.94% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Cutlass Dec. 4 at 8:19 PM

$QNCX In a consolidation mode for now - ⏳

1 · Reply

ConfidencePotato Dec. 4 at 6:31 PM

$QNCX another 52 week high record 🎉

1 · Reply

bullval1 Dec. 4 at 5:07 PM

$QNCX from yesterday's chat: "you could use this for like 100 different diseases potentially" love the sound of that.

1 · Reply

ADSlay Dec. 4 at 3:29 PM

$QNCX highly recommend one listen to yesterday's chat from 9:41 minute mark to 12:50. There is a very important 'tell' in there, not from CEO but from his interviewer.

1 · Reply

ADSlay Dec. 4 at 3:20 PM

$QNCX "Occam's razor is a problem-solving principle stating that the simplest explanation, with the fewest assumptions, is usually the best one." There wasn't as much volume on 11/24 when they announced their road-show as much as it was on 11/10, the day they announced their iDSMB result. Look at the price ever since. Simplest explanation to price action since is people saw signal, a big, fat, beautiful signal.

0 · Reply

MoneyGroupLLC Dec. 4 at 1:10 PM

Enter: $QNCX Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.34 - $0.50 Sell Price: $0.62 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 12, 2025, 4:05 PM EST - 22 days ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 24 days ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 5:12 PM EDT - 2 months ago

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Sep 25, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 24, 2025, 1:13 AM EDT - 2 months ago

Quince Therapeutics, Inc. - Special Call

Sep 11, 2025, 4:05 PM EDT - 3 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 2, 2025, 4:05 PM EDT - 3 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 5 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 6 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 15, 2025, 9:50 AM EDT - 7 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 13, 2025, 8:00 AM EDT - 7 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 7, 2025, 8:00 AM EST - 10 months ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 10 months ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 10 months ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 11 months ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 11 months ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 11 months ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

AtomicAIerts Dec. 5 at 12:52 PM

$QNCX AtomicAlerts Scalp Alert Direction: SHORT Entry: $3.6 TP1: $2.9 | TP2: $2.2 | TP3: $1.5 Stop Loss: $4.2 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 6:49 AM

1ightning® Premium Options Alert (Actionable) Ticker: $QNCX Contract: Dec 19 $2.5C Entry: 1.20 Exit: 1.66 Return: +37.94% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

GrandPoobahofBagholders Dec. 5 at 2:12 AM

$QNCX It sure would be nice to get positive Phase 3 data tomorrow morning!

1 · Reply

Iightning Dec. 5 at 12:38 AM

1ightning® Premium Options Alert (Actionable) Ticker: $QNCX Contract: Dec 19 $2.5C Entry: 1.20 Exit: 1.66 Return: +37.94% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Cutlass Dec. 4 at 8:19 PM

$QNCX In a consolidation mode for now - ⏳

1 · Reply

ConfidencePotato Dec. 4 at 6:31 PM

$QNCX another 52 week high record 🎉

1 · Reply

bullval1 Dec. 4 at 5:07 PM

$QNCX from yesterday's chat: "you could use this for like 100 different diseases potentially" love the sound of that.

1 · Reply

ADSlay Dec. 4 at 3:29 PM

$QNCX highly recommend one listen to yesterday's chat from 9:41 minute mark to 12:50. There is a very important 'tell' in there, not from CEO but from his interviewer.

1 · Reply

ADSlay Dec. 4 at 3:20 PM

0 · Reply

MoneyGroupLLC Dec. 4 at 1:10 PM

0 · Reply

Iightning Dec. 4 at 8:16 AM

1ightning® Premium Options Alert (Actionable) Ticker: $QNCX Contract: Dec 19 $2.5C Entry: 0.97 Exit: 1.52 Return: +55.91% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

SadyK189 Dec. 4 at 4:53 AM

$QNCX Initially alerted at 2.52. Currently at 3.51. Updated key support at 2.65 - 2.90. Next key level to test is 4.10 - 4.30. It may take sometime though. Its looking good on daily as well as weekly chart.

0 · Reply

SadyK189 Dec. 3 at 11:46 PM

$QNCX Price 2.52. My post was "QNCX is trending nicely on daily chart. Key support at 1.95 - 2.10. Next key level to test is 2.9 - 3.1. Currently at 2.52" It went till 3.69 today

0 · Reply

desibre Dec. 3 at 11:31 PM

$QNCX Can somebody explain what effect will Capricor's positive dmd trial have on Quince since a couple of you here have mentioned dmd as a possible application. Thank you!

3 · Reply

iAm_Goatz Dec. 3 at 10:46 PM

$QNCX ouuuuf.. don't be like Shkreli! 💉➡️ ⏳ ➡️ 🔥🩳s

0 · Reply

ADSlay Dec. 3 at 6:20 PM

$QNCX this will happen. I have been listening to Thye for two years and today he was screaming confidence. His humility tempers hype but screams conviction. He has engineered the trial design to set us up for success. Go back and listen to the iDSMB part :)

0 · Reply

ConfidencePotato Dec. 3 at 5:31 PM

$QNCX SMALLER Market Cap = BIGGER % Moves • CAPR: $212M → ~$1.5B (7x) = +600% • QNCX: $88M → $600M-1B (7-11x) = +600-1,000%

1 · Reply

iAm_Goatz Dec. 3 at 5:02 PM

$QNCX

0 · Reply

Sunspotter1 Dec. 3 at 4:41 PM

$QNCX Why not have a charge at $4 today...?

0 · Reply

Sunspotter1 Dec. 3 at 4:14 PM

$QNCX $2-3 B A-T rev estimates are just simply mind-blowing...that's not considering any of the pipeline extensions / tech extensions...this is lining up in the lunacy category of potential.

0 · Reply

ADSlay Dec. 3 at 4:12 PM

$QNCX read this very carefully and see what we have on our hands 💎💎💎

1 · Reply

bullval1 Dec. 3 at 4:12 PM

$QNCX Slighted dissapointed that they didn't discuss some of the additional applications on the call. But overall...$2B to $3B potential revenue just for A-T

1 · Reply

Market Cap	188.20M
Revenue (ttm)	0.00
Net Income (ttm)	-56.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	16.53

Volume	2,163,300
Avg Vol	626,234
Day's Range	N/A - N/A
Shares Out	55.68M
Stochastic %K	93%
Beta	1.03
Analysts	Strong Sell
Price Target	$7.40